Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

I covered Crinetics Pharma (NASDAQ: CRNX ) back in 2023, when it was developing Paltusotine for acromegaly in a phase 3 trial. Now, they have positive data and a September 25 PDUFA date, so let us take a look.About the TPT ServiceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring ...